People's Hospital 115
Ho Chi Minh City, Ho Chi Minh, 700000, Vietnam
Location status: Recruiting
NCT Number: NCT07234955
This observational cohort study evaluates the safety and effectiveness of minimally invasive surgery (MIS) compared with standard medical management in adults with spontaneous deep intracerebral hemorrhage. Consecutive patients admitted to People's Hospital 115 and Tam Anh General Hospital will be enrolled within 72 hours of onset. Clinical and imaging data will be collected prospectively, and outcomes including survival and functional status will be assessed through 180 days.
Interested in participating?
Request Info18 year–80 year
All sexes
Observational
Ho Chi Minh City, Ho Chi Minh, 700000, Vietnam
Location status: Recruiting
Spontaneous deep intracerebral hemorrhage (ICH) is associated with high early mortality and long-term disability. Conventional craniotomy has not consistently improved functional outcomes, while medical management alone often results in poor prognosis. Minimally invasive surgery (MIS), including parafascicular approaches guided by neuronavigation, is designed to evacuate hematomas with reduced disruption of critical white-matter tracts. Evidence supporting MIS is more robust in lobar ICH, whereas data for basal ganglia hemorrhage remain limited. Furthermore, most prior studies restricted surgical intervention to within 24 hours from onset, leaving uncertainty regarding potential benefit when performed between 24 and 72 hours.
This prospective, multicenter, observational cohort study is conducted at People's Hospital 115 and Tam Anh General Hospital. Consecutive patients admitted with spontaneous basal ganglia ICH are enrolled within 72 hours of onset. Decisions regarding MIS, including whether to operate and the timing of surgery, are made by treating clinical teams in routine practice. The study does not assign interventions but documents real-world management and outcomes.
Data are captured prospectively using standardized CRFs and electronic CRFs. Information includes demographics, comorbidities, presenting neurological status, laboratory and imaging findings, details of MIS when performed, intensive care and hospital course, and follow-up assessments through 180 days. The primary endpoint is functional outcome at 180 days, while safety endpoints include mortality and treatment-related complications. Analyses are planned using prespecified multivariable approaches to account for confounding by indication. Additional subgroup analyses will assess outcomes by timing of MIS (0-24 vs 24-72 hours) and other clinically relevant variables.
By focusing on basal ganglia hemorrhage in contemporary Vietnamese stroke centers, this study is intended to generate real-world evidence on the effectiveness and safety of MIS in deep ICH and inform selection criteria and timing for future interventional trials.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 180 days after intracerebral hemorrhage
Proportion of participants achieving favorable functional outcome defined as mRS 0-3.
Unit of Measure: Percentage of participants
Time frame: 180 days after intracerebral hemorrhage
Mean UW-mRS score at 180 days after intracerebral hemorrhage. The UW-mRS is a continuous, utility-weighted measure of functional outcome ranging from 0 (death) to 1 (no symptoms).
Unit of Measure: Score (0-1 scale)
Time frame: 30 days after intracerebral hemorrhage
Number of participants who die from any cause within 30 days after intracerebral hemorrhage.
Unit of Measure: Percentage of participants
Time frame: Within hospitalization and up to 30 days after intracerebral hemorrhage
Incidence of major complications related to minimally invasive surgery or medical management, including but not limited to rebleeding, infection, seizures, or other serious adverse events as judged by the investigators.
Unit of Measure: Number of participants with complications
Time frame: 180 days after intracerebral hemorrhage
Proportion of participants achieving favorable functional outcome (mRS 0-3) at 180 days, compared between patients undergoing minimally invasive surgery (MIS) within 0-24 hours and those undergoing MIS within 24-72 hours after intracerebral hemorrhage.
Unit of Measure: Percentage of participants
Time frame: 30 days after intracerebral hemorrhage
All-cause mortality within 30 days, compared between participants undergoing MIS within 0-24 hours versus 24-72 hours after intracerebral hemorrhage.
Unit of Measure: Percentage of participants.
Time frame: Within hospitalization and up to 30 days after intracerebral hemorrhage
Incidence of major procedure-related complications (e.g., postoperative rebleeding, surgical site infection, CSF leak, clinically significant seizures) during index hospitalization and through 30 days, compared between participants undergoing MIS within 0-24 hours versus 24-72 hours.
Unit of Measure: Number of participants with ≥1 complication
Contact information is provided by the study sponsor or research team.
Huynh Quoc Huy
Other Gov
Evaluation Of The Efficacy And Safety Of Minimally Invasive Surgery In Patients With Spontaneous Deep Intracerebral Hemorrhage
Acronym: MISDIH
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07053917
Brain Diseases, Brain Infarction
Baltimore, Maryland, United States
View Trial DetailsNCT07319013
Brain Diseases, Cardiovascular Diseases
Barcelona, Catalonia, Spain
View Trial DetailsNCT05539859
Brain Diseases, Cardiovascular Diseases
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT06924983
Brain Diseases, Cardiovascular Diseases
Luzhou, China
View Trial Details